ANTXR1 and neoplasm: TEM8 CAR-T cells were also recently postulated as a promising CAR-T-cell-based therapy, in which the TEM8 CAR T cells induce the regression of both established, localized patient-derived xenograft tumours (PDX) and lung metastatic TNBC cell line-derived xenograft tumours, by both killing the TEM8+ TNBC tumour cells and targeting the tumour endothelium to block tumour neovascularization [123].